Oligosaccharide Composition for Microbiome-Mediated IBD Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective treatment options for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, which are chronic relapsing immunologically mediated diseases of the intestine, due to poor understanding of their pathogenesis and limited therapeutic interventions.
Innovation Solution
The use of oligosaccharide compositions characterized by specific multiplicity-edited gradient-enhanced 1H-13C heteronuclear single quantum correlation (HSQC) NMR spectra, which promote the growth of commensal bacteria and increase the levels of short-chain fatty acids like butyrate, acetate, and propionate, thereby treating inflammatory and immune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatment options are used for inflammatory bowel diseases, then current standard therapies are applied, but effective treatment outcomes are not achieved due to lack of novel therapies
Solution Approach 1:
The patent changes the fundamental parameter of treatment approach by shifting from direct anti-inflammatory pharmacological intervention to indirect modulation through microbiome manipulation. The oligosaccharide composition alters the gut microbiota composition, which in turn produces metabolites that exert therapeutic effects on inflammatory bowel disease, representing a paradigm shift in treatment parameters
Solution Approach 2:
The patent introduces the gut microbiome as an intermediary mediator between the administered oligosaccharide composition and the target inflammatory bowel disease. The microbiome metabolizes the oligosaccharides into short-chain fatty acids and other metabolites that then act on the intestinal lining and immune system, providing a novel indirect treatment pathway
2Quantity of substance
If oligosaccharide compositions are used to modulate microbiome, then functional outputs like SCFA production increase, but specific compositional control is required
Solution Approach 1:
The patent applies local quality by specifying particular oligosaccharide structures with defined glycosidic linkages and monomer compositions that selectively promote the growth of specific beneficial bacterial species. The composition is tailored to have particular structural characteristics that match the substrate specificity of commensal bacteria, ensuring localized and targeted metabolic outcomes
Solution Approach 2:
The patent precisely controls compositional parameters including degree of polymerization, glycosidic linkage types, and monomer composition ratios to optimize microbiome modulation. These controlled parameter changes ensure reproducible production of desired metabolites while maintaining safety and efficacy profiles
3Reliability
If oligosaccharide compositions are administered to treat inflammatory bowel disease, then inflammation is reduced and beneficial bacteria increase, but comprehensive characterization of the composition is needed
Solution Approach 1:
The patent employs continuous oligosaccharide administration to maintain sustained modulation of the gut microbiome. The composition is designed for repeated dosing that continuously supplies substrate to beneficial bacteria, ensuring ongoing production of anti-inflammatory metabolites and maintaining therapeutic effects throughout the treatment course
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oligosaccharide compositions effectively reduce inflammation, increase the abundance of beneficial bacteria, and decrease pathogenic bacteria, leading to improved clinical outcomes in inflammatory bowel diseases.
Implementation Method 1
oligosaccharide compositions are useful for increasing levels of short chain fatty acids (SCFAs) such as butyrate, acetate, and/or propionate
Data Source
AI summary
Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for decreasing inflammation for the treatment of inflammatory and immune disorders and diseases.